We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Topical FK506 (Tacrolimus) for Prevention of Immune Reactions Following Penetrating Keratoplasty

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00463723
First Posted: April 20, 2007
Last Update Posted: April 20, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Sucampo Pharmaceuticals, Inc.
Information provided by:
University Hospital Freiburg
  Purpose
Background: Patients following allogeneic keratoplasty are treated with topical and frequently with systemic steroids to prevent immune reactions. Steroids are known to yield good results, but exert a wide range of side effects. The efficacy of topial FK506 in preventing immune reactions has already been demonstrated experimentally. FK506, an IL-2-inhibitor like Cyclosporin A (CSA), is known to be approximately 100 fold more potent than CSA. Aim of the study: In this study the efficacy and safety of topical FK506 will be compared to our standard treatment (i.e. steroids) after penetrating normal-risk keratoplasty.

Condition Intervention Phase
Penetrating Keratoplasty Drug: FK506 0.06% (eye drops) Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Prevention

Resource links provided by NLM:


Further study details as provided by University Hospital Freiburg:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Penetrating keratoplasty for Keratoconus
  • Penetrating keratoplasty for Fuchs endothelial dystrophie
  • Penetrating keratoplasty for Bullous keratopathy

Exclusion Criteria:

  • Glaucoma
  • Limbal stem cell deficiency
  • Herpetic eye disease
  • Repeat Keratoplasty
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00463723


Sponsors and Collaborators
University Hospital Freiburg
Sucampo Pharmaceuticals, Inc.
Investigators
Study Chair: Thomas Reinhard, MD University eye hospital Freiburg, Germany
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00463723     History of Changes
Other Study ID Numbers: FR-2000-2003
First Submitted: April 18, 2007
First Posted: April 20, 2007
Last Update Posted: April 20, 2007
Last Verified: August 1999

Keywords provided by University Hospital Freiburg:
penetrating keratoplasty
graft rejection
immunosuppression

Additional relevant MeSH terms:
Tacrolimus
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action